A Phase 2 interventional study of BMN 111 in Achondroplasia, sponsored by BioMarin Pharmaceutical. Completed at 9 sites in 4 countries. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2021-01-15.
Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Achondroplasia by BioMarin Pharmaceutical — 2 open to participants now, 6 under way, 2 of them phase 3. Achondroplasia · BioMarin Pharmaceutical.
Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2014, is one of 5 in phase 2, and was the 3rd registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →2 of the 14 studies in Achondroplasia by BioMarin Pharmaceutical are open now, in 9 countries. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States, Australia, Canada and 6 more countries
Ages 2–17
BioMarin Pharmaceutical · Sites in United States
Ages 0 mo–18 yrs
By country, each count listing its studies:
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 5 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2014.
This study's enrollment of 35 is below the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 74 across the 10 interventional studies, 185 across the 4 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion Criteria Optional, Open-label Extension Phase:
Exclusion Criteria:
Have any of the following:
Have a history of any of the following:
Cardiac or vascular disease, including the following:
Have an showing any of the following:
Additional Exclusion Criteria for Optional, Open-label Extension Phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1: 2.5 ug/kg
Drug: BMN 111
Cohort 2: 7.5 ug/kg,
Drug: BMN 111
Cohort 3: 15 ug/Kg
Drug: BMN 111
Cohort 4: 30 ug/kg
Drug: BMN 111
BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
Also known as: Modified recombinant human C-type natriuretic peptide, Vosoritide
Overall Summary of Adverse Events During Initial 6-Month Period
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. Serious adverse event (SAE).
Time frame: Up to Month 6 ± 7 Days
Overall Summary of Adverse Events During Entire Study Period
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. TEAE - Treatment-emergent adverse event. SAE - Serious adverse event.
Time frame: Up to Month 25 ± 7 Days
Change From Baseline in Annualized Growth Velocity (AGV) During Initial 6-Month
Annualized Growth Velocity at Day 183 is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.
Time frame: At 6 month (Day 183)
Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 3 and 4
Annualized Growth Velocity at Day 183 visit is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.
Time frame: At month 24
Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 1 and 2 Switchers
Annualized Growth Velocity at 1st visit with \>= 12 months on 15ug/kg is assessed on standing height as ((Height at 1st Visit with \>= 12 Months on 15 μg/kg - Height at 1st Visit on 15 μg/kg)/(Date of the 1st Visit with \>= 12 months on 15 μg/kg - Date of at 1st Visit on 15 μg/kg)) x 365.25.
Time frame: At month 24
Change From Baseline in Height Z-Scores Using Centers for Disease Control and Prevention (CDC) Reference Standard During Initial 6-Months
Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 Standard Deviation Scores (SDs) indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).
Time frame: At month 6 (Day 183)
Change From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 3 and 4
Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 SDs indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).
Time frame: At month 24
Change From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 1 and 2 Switchers
Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 SDs indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).
Time frame: At month 24
Change From Baseline in Upper to Lower Body Ratios During Initial 6-Months
The Upper to Lower Body ratio prior to treatment, at baseline, and through 6 months is assessed on Sitting Height / (Standing Height - Sitting Height)
Time frame: At month 6 (Day 183)
Change From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 3 and 4
The Upper to Lower Body ratio prior to treatment, at baseline, and through 24 months is assessed on Sitting Height / (Standing Height - Sitting Height)
Time frame: At month 24
Change From Baseline in Upper Arm Length to Lower Arm (Forearm) Length Ratio During Initial 6-Months
The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 6 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.
Time frame: At month 6 (Day 183)
Change From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 3 and 4
The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 24 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.
Time frame: At month 24
Change From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 1 and 2 Switchers
The Upper to Lower Body ratio prior to treatment, at baseline, and through 24 months is assessed on Sitting Height / (Standing Height - Sitting Height)
Time frame: At month 24
Change From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers
The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 24 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.
Time frame: At month 24
Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Initial 6-months
The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 6 months is assessed on Upper Leg Length (Thigh) / Knee to Heel Length.
Time frame: At month 6 (Day 183)
Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 3 and 4
The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh) / Knee to Heel Length.
Time frame: At month 24
Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers
The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh) / Knee to Heel Length.
Time frame: At month 24
Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Initial 6-months
The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 6 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.
Time frame: At month 6 (Day 183)
Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 3 and 4
The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.
Time frame: At month 24
Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers
The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.
Time frame: At month 24
Change From Baseline in Arm Span to Height Ratio During Initial 6-months
The Arm Span to Height Ratio prior to treatment, at baseline, and through 6 months is assessed by Arm Span / Standing Height.
Time frame: At month 6 (Day 183)
Change From Baseline in Arm Span to Height Ratio During Entire Study Period - Cohort 3 and 4
The Arm Span to Height Ratio prior to treatment, at baseline, and through 24 months is assessed by Arm Span / Standing Height.
Time frame: At month 24
Change From Baseline in Arm Span to Height Ratio During Entire Study Period - Cohort 1 and 2 Switchers
The Arm Span to Height Ratio prior to treatment, at baseline, and through 24 months is assessed by Arm Span / Standing Height. Values are not available for participants in cohort 1 switchers for Change from Baseline to \>=12 Months on 15ug/kg.
Time frame: At month 24
This study was conducted at nine study centers in United States, Australia, United Kingdom and France.
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Started | 8 | 8 | 10 | 9 |
| Completed | 7 | 7 | 10 | 8 |
| Not completed | 1 | 1 | 0 | 1 |
| Withdrew: Subject discontinued due to needlephobia | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Consent withdrawn by subject | 1 | 0 | 0 | 0 |
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Started | 7 | 7 | 10 | 8 |
| Completed | 6 | 6 | 10 | 8 |
| Not completed | 1 | 1 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 1 | 0 | 0 |
| Withdrew: Subject discontinued due to needlephobia | 1 | 0 | 0 | 0 |
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. Serious adverse event (SAE).
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Subjects with at Least 1 Reported TEAE | 8 | 8 | 10 | 9 |
| Subjects Least Reported Study Drug-Related TEAE | 7 | 8 | 9 | 9 |
| Subjects with at Least 1 Reported SAE | 0 | 0 | 0 | 0 |
| Subjects Least Reported Study Drug-Related SAE | 0 | 0 | 0 | 0 |
| Subjects Who Died | 0 | 0 | 0 | 0 |
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. TEAE - Treatment-emergent adverse event. SAE - Serious adverse event.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Subjects with at Least 1 Reported TEAE | 8 | 8 | 10 | 9 |
| Subjects Least Reported Study Drug-Related TEAE | 7 | 8 | 9 | 9 |
| Subjects with at Least 1 Reported SAE | 1 | 0 | 1 | 1 |
| Subjects Least Reported Study Drug-Related SAE | 0 | 0 | 0 | 0 |
| Subjects Who Died | 0 | 0 | 0 | 0 |
Annualized Growth Velocity at Day 183 is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.
| cm/year | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Baseline | 3.755 ± 1.1094 | 2.891 ± 1.3920 | 4.044 ± 2.2751 | 4.492 ± 1.1889 |
| Change from Baseline to Day 183 | -0.371 ± 1.5920 | 1.276 ± 1.4387 | 2.014 ± 1.9990 | 2.085 ± 2.1375 |
Annualized Growth Velocity at Day 183 visit is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.
| cm/year | Cohort 3 | Cohort 4 |
|---|---|---|
| Baseline | 4.044 ± 2.2751 | 4.492 ± 1.1889 |
| Change from Baseline to Month 24 | 1.744 ± 1.7974 | 1.538 ± 1.3387 |
Annualized Growth Velocity at 1st visit with \>= 12 months on 15ug/kg is assessed on standing height as ((Height at 1st Visit with \>= 12 Months on 15 μg/kg - Height at 1st Visit on 15 μg/kg)/(Date of the 1st Visit with \>= 12 months on 15 μg/kg - Date of at 1st Visit on 15 μg/kg)) x 365.25.
| cm/year | Cohort 1 | Cohort 2 |
|---|---|---|
| Baseline | 3.629 ± 1.1586 | 3.510 ± 0.8327 |
| Change from Baseline at >=12 Months on 15μg/kg | 1.846 ± 2.1466 | 2.245 ± 0.9176 |
Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 Standard Deviation Scores (SDs) indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).
| z score | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Baseline | -6.056 ± 0.6331 | -5.145 ± 0.8530 | -4.613 ± 1.1355 | -5.193 ± 0.7486 |
| Change from Baseline to Day 183 | -0.008 ± 0.1788 | 0.078 ± 0.1440 | 0.229 ± 0.1505 | 0.265 ± 0.1869 |
Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 SDs indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).
| z score | Cohort 3 | Cohort 4 |
|---|---|---|
| Baseline | -4.613 ± 1.1355 | -5.193 ± 0.7486 |
| Change from Baseline to Month 24 | 0.788 ± 0.2842 | 0.896 ± 0.3010 |
Height Z scores indicates how far a particular child is from the average height for children of the same sex and age. A positive height Z score indicates the child's height is above average whilst a negative Z score indicates the child's height is below average. Height Z scores below -2 SDs indicate a child's height is no longer within normal height range for average stature children of the same sex and age. Z-scores are derived using non-ACH age-sex-specific reference data (means and standard deviations) per Centers for Disease Control and Prevention (CDC).
| z score | Cohort 1 | Cohort 2 |
|---|---|---|
| Baseline | -6.064 ± 0.6932 | -4.912 ± 0.7708 |
| Change from Baseline to >=12 Months on 15ug/kg | 0.520 ± 0.2950 | 0.259 ± 0.1887 |
The Upper to Lower Body ratio prior to treatment, at baseline, and through 6 months is assessed on Sitting Height / (Standing Height - Sitting Height)
| Ratio | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Baseline | 2.094 ± 0.0984 | 2.027 ± 0.1793 | 1.911 ± 0.2286 | 1.962 ± 0.1822 |
| Change from Baseline to Day 183 | -0.021 ± 0.0626 | 0.003 ± 0.0510 | -0.024 ± 0.0369 | -0.030 ± 0.0811 |
The Upper to Lower Body ratio prior to treatment, at baseline, and through 24 months is assessed on Sitting Height / (Standing Height - Sitting Height)
| ratio | Cohort 3 | Cohort 4 |
|---|---|---|
| Baseline | 1.911 ± 0.2286 | 1.962 ± 0.1822 |
| Change from Baseline to Month 24 | -0.067 ± 0.0451 | -0.121 ± 0.1058 |
The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 6 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.
| ratio | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Baseline | 1.130 ± 0.1168 | 1.143 ± 0.0924 | 1.130 ± 0.1190 | 1.106 ± 0.0816 |
| Change from Baseline to Day 183 | -0.019 ± 0.0623 | 0.001 ± 0.0521 | -0.048 ± 0.1002 | 0.003 ± 0.0869 |
The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 24 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.
| ratio | Cohort 3 | Cohort 4 |
|---|---|---|
| Baseline | 1.130 ± 0.1190 | 1.106 ± 0.0816 |
| Change from Baseline to Month 24 | 0.037 ± 0.0673 | -0.027 ± 0.0504 |
The Upper to Lower Body ratio prior to treatment, at baseline, and through 24 months is assessed on Sitting Height / (Standing Height - Sitting Height)
| ratio | Cohort 1 | Cohort 2 |
|---|---|---|
| Baseline | 2.119 ± 0.0812 | 2.053 ± 0.1746 |
| Change from Baseline to >=12 Months on 15ug/kg | -0.078 ± 0.0452 | -0.078 ± 0.1271 |
The Upper Arm Length to Lower Arm (Forearm) Length ratio prior to treatment, at baseline, and through 24 months is assessed on Upper Arm Length / Lower Arm (Forearm) Length.
| ratio | Cohort 1 | Cohort 2 |
|---|---|---|
| Baseline | 1.131 ± 0.1280 | 1.114 ± 0.0520 |
| Change from Baseline to >=12 Months on 15ug/kg | 0.009 ± 0.0056 | -0.004 ± 0.1181 |
The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 6 months is assessed on Upper Leg Length (Thigh) / Knee to Heel Length.
| ratio | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Baseline | 0.672 ± 0.0600 | 0.662 ± 0.0585 | 0.687 ± 0.0268 | 0.691 ± 0.0847 |
| Change from Baseline to Day 183 | -0.002 ± 0.0401 | -0.006 ± 0.0462 | 0.007 ± 0.0411 | -0.006 ± 0.0810 |
The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh) / Knee to Heel Length.
| ratio | Cohort 3 | Cohort 4 |
|---|---|---|
| Baseline | 0.687 ± 0.0268 | 0.691 ± 0.0847 |
| Change from Baseline to Month 24 | 0.010 ± 0.0503 | -0.033 ± 0.1065 |
The Upper Leg Length (Thigh) to Knee to Heel Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh) / Knee to Heel Length.
| ratio | Cohort 1 | Cohort 2 |
|---|---|---|
| Baseline | 0.659 ± 0.0541 | 0.673 ± 0.0579 |
| Change from Baseline to >=12 Months on 15ug/kg | 0.002 ± 0.0228 | 0.006 ± 0.0618 |
The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 6 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.
| ratio | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Baseline | 1.089 ± 0.1067 | 1.074 ± 0.1350 | 1.107 ± 0.0607 | 1.061 ± 0.1341 |
| Change from Baseline to Day 183 | 0.001 ± 0.0774 | 0.007 ± 0.0863 | 0.034 ± 0.1048 | 0.015 ± 0.1571 |
The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.
| ratio | Cohort 3 | Cohort 4 |
|---|---|---|
| Baseline | 1.107 ± 0.0607 | 1.061 ± 0.1341 |
| Change from Baseline to Month 24 | 0.014 ± 0.0888 | -0.012 ± 0.1477 |
The Upper Leg Length (Thigh) to Tibial Length Ratio prior to treatment, at baseline, and through 24 months is assessed by Upper Leg Length (Thigh)/ Tibial Leg Length.
| ratio | Cohort 1 | Cohort 2 |
|---|---|---|
| Baseline | 1.080 ± 0.1139 | 1.100 ± 0.1447 |
| Change from Baseline to >=12 Months on 15ug/kg | -0.020 ± 0.0297 | 0.018 ± 0.1602 |
The Arm Span to Height Ratio prior to treatment, at baseline, and through 6 months is assessed by Arm Span / Standing Height.
| ratio | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Baseline | 0.901 ± 0.0189 | 0.889 ± 0.0906 | 0.913 ± 0.0123 | 0.893 ± 0.0284 |
| Change from Baseline to Day 183 | 0.012 ± 0.0111 | -0.005 ± 0.0079 | 0.007 ± 0.0063 | 0.001 ± 0.0143 |
The Arm Span to Height Ratio prior to treatment, at baseline, and through 24 months is assessed by Arm Span / Standing Height.
| ratio | Cohort 3 | Cohort 4 |
|---|---|---|
| Baseline | 0.911 ± 0.0119 | 0.900 ± 0.0315 |
| Change from Baseline to Month 24 | 0.000 ± 0.0123 | -0.006 ± 0.0290 |
The Arm Span to Height Ratio prior to treatment, at baseline, and through 24 months is assessed by Arm Span / Standing Height. Values are not available for participants in cohort 1 switchers for Change from Baseline to \>=12 Months on 15ug/kg.
| ratio | Cohort 2 |
|---|---|
| Baseline | 0.881 ± 0.0480 |
| Change from Baseline to >=12 Months on 15ug/kg | -0.014 ± 0.0179 |
Collected over Up to Month 25 ± 7 Days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial 6-Months Period 2.5 µg/kg. | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Initial 6-Months Period 7.5 µg/kg. | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Initial 6-Months Period 15 µg/kg. | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Initial 6-Months Period 30 µg/kg. | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Extension Period 2.5 µg/kg. | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Extension Period 7.5 µg/kg. | 0/14 (0%) | 0/14 (0%) | 13/14 (92.9%) |
| Extension Period 15 µg/kg. | 0/22 (0%) | 1/22 (4.5%) | 22/22 (100%) |
| Extension Period 30 µg/kg. | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Entire Study Period 2.5 µg/kg. | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Entire Study Period 7.5 µg/kg. | 0/15 (0%) | 0/15 (0%) | 14/15 (93.3%) |
| Entire Study Period 15 µg/kg. | 0/22 (0%) | 1/22 (4.5%) | 22/22 (100%) |
| Entire Study Period 30 µg/kg. | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| Event | Initial 6-Months Period 2.5 µg/kg. | Initial 6-Months Period 7.5 µg/kg. | Initial 6-Months Period 15 µg/kg. | Initial 6-Months Period 30 µg/kg. | Extension Period 2.5 µg/kg. | Extension Period 7.5 µg/kg. | Extension Period 15 µg/kg. | Extension Period 30 µg/kg. | Entire Study Period 2.5 µg/kg. | Entire Study Period 7.5 µg/kg. | Entire Study Period 15 µg/kg. | Entire Study Period 30 µg/kg. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/10 | 0/9 | 1/7 | 0/14 | 0/22 | 0/8 | 1/8 | 0/15 | 0/22 | 0/9 |
| Thyroglossal cystCongenital, familial and genetic disorders | 0/8 | 0/8 | 0/10 | 0/9 | 0/7 | 0/14 | 0/22 | 1/8 | 0/8 | 0/15 | 0/22 | 1/9 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/10 | 0/9 | 0/7 | 0/14 | 1/22 | 0/8 | 0/8 | 0/15 | 1/22 | 0/9 |
| Event | Initial 6-Months Period 2.5 µg/kg. | Initial 6-Months Period 7.5 µg/kg. | Initial 6-Months Period 15 µg/kg. | Initial 6-Months Period 30 µg/kg. | Extension Period 2.5 µg/kg. | Extension Period 7.5 µg/kg. | Extension Period 15 µg/kg. | Extension Period 30 µg/kg. | Entire Study Period 2.5 µg/kg. | Entire Study Period 7.5 µg/kg. | Entire Study Period 15 µg/kg. | Entire Study Period 30 µg/kg. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 2/8 | 6/8 | 8/10 | 9/9 | 2/7 | 5/14 | 15/22 | 6/8 | 2/8 | 8/15 | 17/22 | 9/9 |
| Injection site erythemaGeneral disorders | 4/8 | 7/8 | 9/10 | 9/9 | 1/7 | 5/14 | 11/22 | 6/8 | 4/8 | 7/15 | 14/22 | 9/9 |
| Injection site swellingGeneral disorders | 4/8 | 2/8 | 4/10 | 2/9 | 0/7 | 0/14 | 8/22 | 1/8 | 4/8 | 2/15 | 8/22 | 2/9 |
| PyrexiaGeneral disorders | 4/8 | 1/8 | 3/10 | 2/9 | 0/7 | 1/14 | 5/22 | 1/8 | 4/8 | 2/15 | 7/22 | 2/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/8 | 0/8 | 2/10 | 4/9 | 0/7 | 2/14 | 4/22 | 1/8 | 4/8 | 2/15 | 6/22 | 4/9 |
| HeadacheNervous system disorders | 4/8 | 2/8 | 2/10 | 3/9 | 1/7 | 1/14 | 5/22 | 0/8 | 4/8 | 3/15 | 6/22 | 3/9 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/8 | 0/8 | 0/10 | 1/9 | 0/7 | 0/14 | 2/22 | 4/8 | 1/8 | 0/15 | 2/22 | 4/9 |
| HypotensionVascular disorders | 3/8 | 4/8 | 4/10 | 2/9 | 1/7 | 1/14 | 3/22 | 2/8 | 4/8 | 5/15 | 7/22 | 2/9 |
| Injection site urticariaGeneral disorders | 1/8 | 1/8 | 2/10 | 3/9 | 1/7 | 1/14 | 3/22 | 1/8 | 1/8 | 2/15 | 3/22 | 4/9 |
| NasopharyngitisInfections and infestations | 1/8 | 3/8 | 3/10 | 1/9 | 0/7 | 1/14 | 4/22 | 2/8 | 1/8 | 3/15 | 7/22 | 2/9 |
Safety Analysis Population consists of all subjects who received at least one dose of study treatment and were used for safety analysis in the initial 6-month period and entire study period.
| Age, Continuous(yrs) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Mean | 7.3 ± 1.58 | 8.3 ± 2.19 | 8.0 ± 1.63 | 6.9 ± 1.17 | 7.6 ± 1.68 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Female | 5 | 3 | 6 | 5 | 19 |
| Male | 3 | 5 | 4 | 4 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 | 2 |
| Not Hispanic or Latino | 8 | 8 | 9 | 7 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| White | 7 | 6 | 5 | 6 | 24 |
| Asian | 0 | 1 | 3 | 3 | 7 |
| Black or African American | 1 | 0 | 1 | 0 | 2 |
| Other | 0 | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2014 to primary completion in Oct 2017, 44 months.
Results were first posted in Jan 2021, 3 years 3 months after primary completion. A results delay was requested in Sep 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vosoritide